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Reply from the Authors
Thank you for calling our attention to the importance
of anion exchange of chloride for short-chain fatty acid
anions (SSFAA) as a potential mechanism of sevelamer-
induced metabolic acidosis. To the best of our knowl-
edge, no data have been published regarding the relative
binding affinity of sevelamer hydrochloride (a quater-
nary amine anion exchange resin) for the various an-
ions present in the intestinal lumen (phosphates, sulfates,
bicarbonate, carbonate, citrate, bile acids, acetate, and
other SSFAA). However, it seems likely that binding
of SSFAA by sevelamer in the large intestine may well
be a major factor in the genesis of sevelamer-induced
metabolic acidosis, as you suggest. Final equilibration in
the gut with binding of SSFAA, bicarbonate, and bile
acids to the sevelamer resin, resulting in displacement of
phosphate, may also help to explain the well known dis-
crepancy between the in vitro and in vivo phosphate bind-
ing efficacy of sevelamer. In dialysis patients with refrac-
tory hyperphosphatemia, it has been recommended that
sevelamer and calcium acetate or calcium carbonate be
used concomitantly [1]. However, it is theoretically pos-
sible that simultaneous use of calcium-based phosphate
binders containing acetate or carbonate could further re-
duce the phosphate-binding efficacy of sevelamer. These
considerations suggest that an optimal strategy may be to
alternate use of sevelamer and calcium-based phosphate
binders with different meals during the day. Moreover, if
sodium bicarbonate supplements are needed to maintain
serum bicarbonate above 22 mEq/L, as recommended
by K/DOQI guidelines [2], the oral bicarbonate supple-
ment should probably not be ingested at the same time
as sevelamer to avoid competition between bicarbonate
and phosphate for binding to the resin.
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Kidney function itself, and not
cystatin C, is correlated with
height and weight
To the Editor: In a recent issue of this journal [1],
Knight et al presented data from a large population study
on factors influencing serum cystatin C concentrations in
adults. After adjustment for uncorrected creatinine clear-
ance (in mL/min), multivariate linear regression analysis
yielded a significant positive correlation of cystatin C with
age, male gender, weight, height, cigarette smoking, and
C-reactive protein (CRP) levels.
Traditionally, glomerular filtration rate (GFR) is nor-
malized to 1.73m2 body surface area (BSA) [2], which
is of particular importance in growing subjects. There-
fore, almost all papers correlating cystatin C with a gold-
standard GFR were indexed to BSA. When looked at,
anthropomorphometric data did not influence the cor-
relation between GFR normalized for BSA and serum
cystatin C [3].
It is therefore not surprising that Knight et al [1] identi-
fied height and weight—the chief determinants of BSA—
as confounding variables for both cystatin C and creati-
nine when studying correlation with uncorrected GFR.
It would be interesting to see which effect normalization
of creatinine clearance to BSA has on the other correla-
tions reported. Their large cohort is certainly particularly
well suited to identify factors weakly influencing serum
cystatin C concentration that have been missed so far.
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Table 1. Factors that were found associated with serum cystain C after adjusting for uncorrected creatinine clearance (first column)
Adjusted for Ccr Adjusted for BSA corr Ccr Adjusted for height corr Ccr
Beta st err P Beta st err P beta st err P
Weight kg .002 2.79 × 10−4 <.001 .000 2.62 × 10−4 .212 .002 2.79 × 10−4 <.001
Height cm .002 4.66 × 10−4 <.001 .001 4.67 × 10−4 .022 .001 4.69 × 10−4 .146
Age years .004 2.87 × 10−4 <.001 .004 2.88 × 10−4 <.001 .004 2.87 × 10−4 <.001
Gendera −.066 .008 <.001 −.066 .008 <.001 −.066 .008 <.001
Smokinga .051 .006 <.001 .051 .006 <.001 .051 .006 <.001
Ln CRP mg/L .038 .003 <.001 .038 .003 <.001 .038 .003 <.001
In columns 2 and 3 the same associations are presented after adjusting for BSA corrected or height corrected creatinine clearance.
aReference for gender is male gender, and for smoking is nonsmokers.
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Reply from the Authors
Dr. Bo¨kenkamp comments on our message that it is
of importance to take height and weight into account
when using serum cystatin C level as a measure for re-
nal function [1]. We found that height and weight were
associated with serum cystatin C when we adjusted for
creatinine clearance (Ccr) uncorrected for body surface
area (BSA).They argue that the associations between
weight and height and cystatin C probably will disappear
when we adjust for BSA corrected Ccr instead of uncor-
rected Ccr. They understandably raise that question be-
cause GFR generally is normalized to 1.73m2 BSA (which
is determined by both height and weight), especially in
growing subjects.
We, by purpose, had chosen not to adjust for BSA cor-
rected Ccr because this might mask a potential effect of
obesity. In adults, weight generally has more impact on
BSA than height. This has led to the suggestion that it
would be better to use GFR measurements corrected for
height rather than BSA [2]. In Table 1, we therefore plot
the association of the linear regression model of weight
and height and cystatin C after adjusting for uncorrected
Ccr (first column), for BSA corrected Ccr (second col-
umn), and for height corrected Ccr(third column).
As expected, the associations of weight and height
with serum cystatin C were lower or even absent in the
model using BSA adjusted Ccr, but the association be-
tween weight and serum cystatin C remained identical in
the model, in which we adjusted for height corrected Ccr
in our adults of 28 to 75 years of age.
Bo¨kenkamp also questions what happens with the
other factors associated with cystatin C, that is age, gen-
der, smoking, and CRP when we adjust for BSA or
height corrected Ccr. As can be seen from the Table,
those associations remained completely identical in both
new models compared to the original model. This indi-
cates that factors other than body size are responsible for
the associations of age, gender, smoking, and CRP with
cystatin C.
We should realize that we presently accept serum cre-
atinine only as an appropriate marker of renal function
when we take into account age, gender, and weight. This
is common practice in the serum creatinine derived for-
mulas to estimate renal function. In that respect, it should
be welcomed that recently a formula has also been intro-
duced to calculate GFR (in mL/min) from plasma cys-
tatin C values (in mg/L). Based upon measurements of
serum cystatin C (by Dade Behring assay) and of iohexol
measured GFR, Larsson et al calculated GFR as (77.24 ×
serum cystatin C)−1.2623 [3]. Remarkably, these authors
did not take into account any of the above described vari-
ables in their formula.
Using that formula instead of serum cystatin C level,
the associations in the above-mentioned three models did
not change significantly. This implies that, when using cys-
tatin C as measure of renal function, a cystatin C–based
formula should be designed to take into account at least
age, gender, and weight, just as in the creatinine-based
formulas to estimate renal function.
In addition, further studies are needed to investigate
the association between inflammation (as reflected by
CRP) and cystatin C levels. Because CRP was found in-
dependently associated with serum cystatin C, and be-
cause CRP levels are found associated with progressive
atherosclerosis [4], it might well be that cystatin C is a
good marker for renal function because it, better than
creatinine, reflects the extent of atherosclerosis accom-
panying impaired renal function.
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